This article is more than 5 years old. Information may no longer be current.

Eight important updates in blood cancer treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

September is designated as National Blood Cancer Awareness Month.

In conjunction with the observation, HemOnc Today presents eight important updates in the treatment of leukemia, lymphoma, myeloma, myeloproliferative neoplasms and bone marrow transplantation that may be relevant to your practice.

• The addition of rituximab (Rituxan; Genentech, Biogen) to standard chemotherapy improved EFS in adults with CD20–positive, Philadelphia chromosome–negative B-lineage acute lymphoblastic leukemia. Read more.
• Receipt of mogamulizumab (Poteligeo, Kyowa Hakko Kirin) prior to allogeneic hematopoietic stem cell transplantation significantly increased risk for graft-versus-host disease–related mortality in adults with T-cell leukemia/lymphoma. Read more.
• Treatment with brentuximab vedotin (Adcetris, Seattle Genetics) and chemotherapy, followed by involved-site radiation therapy, induced a high rate of complete response in patients with early-stage, unfavorable risk classical Hodgkin lymphoma. Read more.
• The addition of selinexor (KPT-330, Karyopharm Therapeutics) to low-dose dexamethasone appeared active in patients with heavily pretreated multiple myeloma. Read more.
• Patients with acute leukemia or myelodysplastic syndrome who had pretransplantation minimal residual disease achieved comparable outcomes after receipt of a hematopoietic cell transplantation from an umbilical cord blood source or HLA–matched unrelated donor. Read more.
• Quantifying minimal residual disease improved PFS predictions in patients with chronic lymphocytic leukemia who achieved a partial or complete response. Read more.
• The FDA expanded the approval of blinatumomab (Blincyto, Amgen) to include treatment of pediatric patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read more.
• Pacritinib (CTI BioPharma) improved response rate in spleen volume reduction but failed to lead to a greater than 50% reduction in total symptom score among high-risk patients with myelofibrosis. Read more.